Rituximab therapy for Type I membranoproliferative glomerulonephritis

Area of Science:

• Nephrology
• Immunology
• Clinical Trials

Background:

• Type I membranoproliferative glomerulonephritis (MPGN) is an immune-complex kidney disease with a poor prognosis and no established adult treatments.
• B-cell depletion using rituximab, an anti-CD20 monoclonal antibody, was hypothesized to be a potential therapeutic strategy.

Purpose of the Study:

• To evaluate the efficacy of rituximab in treating Type I MPGN in adult patients.
• To assess the impact of B-cell depletion on proteinuria and renal function in Type I MPGN.

Main Methods:

• An open-label trial involving 6 adult patients with Type I MPGN (4 idiopathic, 2 with cryoglobulinemia).
• Rituximab was administered intravenously at 1,000 mg on Day 1 and Day 15.
• Patients were monitored for 1 year, with proteinuria as the primary outcome measure.

Main Results:

• Rituximab successfully suppressed peripheral blood B cells in all patients.
• Mean proteinuria decreased from 3.9 ± 2.0 g/d to a minimum of 1.4 ± 1.4 g/d at 9 months, with statistically significant reductions at 6, 9, and 12 months (p < 0.05).
• Two complete and three partial remissions were observed; creatinine clearance remained stable, and no adverse effects were reported.

Conclusions:

• Rituximab treatment led to a significant reduction in proteinuria for patients with Type I MPGN.
• The findings suggest a potential role for B cells in the pathogenesis of Type I MPGN.
• Further investigation into B-cell suppression as a therapeutic approach for Type I MPGN is warranted.